Clinical Trials in Rheumatology in Ahmedabad
Dr. Dhaiwat Shukla has actively participated in multiple national and international clinical trials in the field of rheumatology and autoimmune diseases. His experience includes working as Principal Investigator, Co-Investigator, and Study Physician in research studies related to Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Osteoporosis, Ankylosing Spondylitis, Systemic Sclerosis, and other immune-mediated disorders. These studies help bring innovative and evidence-based treatments closer to patients while contributing to advancements in rheumatology care.
| Trial indication | Role | Drug | CTRI No |
|---|---|---|---|
| SLE(Minor organ) | Co Investigator | Cenerimod | CTRI/2025/07/090130 |
| SLE minor organ | Principal Investigator | ESK-001 | CTRI/2023/12/060518 |
| SLE minor organ | Co Investigator | BRAVE study Baricitinib phase 3 | CTRI/2019/04/018378 |
| Systemic Sclerosis | Principal Investigator | Anifrolumab | CTRI/2022/02/040015 |
| Osteoporosis | Principal Investigator | Teriparatide | CTRI/2021/04/032769 |
| Osteoporosis | Principal Investigator | Denosumab | CTRI/2021/09/036190 |
| Osteoporosis | Principal Investigator | Teriparatide | CTRI/2023/08/056205 |
| SLE with Lupus Nephritis | Anifrolumab | ||
| Ankylosing Spondylitis | Principal Investigator | Adalimumab | CTRI/2023/11/059396 |
| Psoriatic Arthritis | Principal Investigator | Ixekizumab | CTRI/2023/06/053776 |
| Psoriatic arthritis | Co Investigator | Apremilast Phase 4 | CTRI/2019/01/017122 |
| Rheumatoid arthritis | Otilimab (ContRAst-1) Phase 3/PK | ||
| Rheumatoid Arthritis | Principal Investigator | Adalimumab | CTRI/2023/11/059396 |
| Rheumatoid Arthritis | ------- | ||
| Rheumatoid Arthritis | VELLORA | ||
| Osteoarthritis | Denatured Collagen | ||
| Diabetes mellitus | Co Investigator | Orforglipron | CTRI/2023/10/058480 |
| Diabetes Mellitus type-2 | Principal Investigator | Deglusterol | CTRI/2023/07/054724 |
| Diabetes Mellitus type 2 | Co Investigator | Thymoquinone | CTRI/2021/08/036060 |
| Diabetes mellitus type II | Principal Investigator | Retatrutide | CTRI/2023/10/058324 |
| Diabetes Mellitus type II | Principal Investigator | Dulaglutide | CTRI/2022/12/048337 |
| Yellow Fever | Vaccine | ||
| Recurrent Staph Aureus Infection | Vaccine | ||
| HIV | Principal Investigator | HRF-10071 | CTRI/2022/02/040532 |
| HIV | Principal Investigator | HRF-10071 | CTRI/2022/12/048577 |
| Rabies | Co Investigator | Vaccine/Anti Rabies Immunoglobulin | CTRI/2019/06/019622 |
| Dengue | Co Investigator | Dengue mAb | CTRI/2021/07/035290 |
| COVID 19(Vaccine) | m-RNA vaccine as a booster | ||
| COVID-19 | Principal Investigator | Guduchyadi/Tinos pora Cordifolia | CTRI/2022/07/044204 |
| COVID 19 | --------- | ||
| COVID 19 | mAb Cocktail ZRC3308 | ||
| COVID 19 | Principal Investigator | Molnupiravir | CTRI/2021/07/034588 |
| COVID 19 | Ashwagandha | ||
| COVID 19 | Chlorphylin | ||
| COVID 19 | Inosine Phase 3 | ||
| COVID 19 | Thymoquinone Phase 2/3 | ||
| COVID 19 | Thymoquinone Phase 2/3 | ||
| Anaemia | Ferric Carboxy Maltose | ||
| Chronic Constipation | Principal Investigator | Linaclotide | CTRI/2023/05/052685 |
| Post Operative Pain | Co Investigator | Paracetamol | CTRI/2023/05/052794 |